Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

MilliporeSigma’s Curiosity Cube tours North America, Europe, and for the first time, Africa. In 2025, the mobile science lab ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Germany’s Merck KGaA (DE:MRK) is in advanced talks to buy U.S.-based SpringWorks Therapeutics (SWTX) for roughly $3.5 billion, aiming to boost ...

Stocks surged into the close Thursday after a wobbly start, with all major indexes ending firmly in the green. The Nasdaq led ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump’s ...

Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China.